EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world success of de-escalating upadacitinib induction dosing in ulcerative colitis is predicted by steroid-free clinical and biochemical remission, not induction duration

Raj M Dalal iD, Sarah Rotondo-Trivette iD, Alec R Mason iD, Lynn Leveille iD, Jianyi Yin iD, Chelsea Missi iD, Moheb Boktor iD, David I Fudman iD

Crohn’s & Colitis 360 · 05.10.2026 · 8 (4)

DOI: 10.1093/crocol/otag111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Crohn’s & Colitis 360, online erschienen am 29.10.2026. Verfasst von Raj M Dalal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data guiding upadacitinib dose de-escalation in ulcerative colitis (UC) are limited. We evaluated factors associated with UC-related complications (UCRC) after upadacitinib was reduced from 45 mg daily.

Methods

This retrospective study included adults with UC at a tertiary center who underwent upadacitinib de-escalation (4/2022-11/2025). The primary outcome was a 12-month composite of UCRC (upadacitinib re-escalation or discontinuation, new systemic steroids, new advanced therapy, hospitalization, or colectomy). Predictors of UCRC after de-escalation were assessed using Cox proportional hazards modeling, including steroid-free clinical remission (SFCR), defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0 without systemic steroid use, and biochemical remission, defined as a fecal calprotectin (FC) < 150 μg/g or a C-reactive protein (CRP) < 5 mg/L when FC was unavailable. Optimal CRP and FC cut points were identified via ROC curves.

Results

Among 70 patients, 25 (35.7%) experienced UCRC (median follow-up 56 weeks). Induction duration, prior advanced therapy exposure, and endoscopic severity did not differ significantly between those with and without UCRC. Patients without UCRC were more likely to have achieved SFCR (51.1% vs 20.0%, P=.01) and biochemical remission (53.3% vs 28.0%, P=.04) prior to de-escalation, with lower median CRP (0.8 vs 1.5 mg/L, P=.04) and FC (79.5 vs 208.0 μg/g, P=.03). In multivariable analysis, achieving SFCR (aHR 0.33, 95% CI, 0.12-0.91) and biochemical remission (aHR 0.34, 95% CI, 0.13-0.85) independently predicted lower UCRC risk, and achieving both conferred additional UCAE-free survival benefit. Optimal cut points predicting UCRC were CRP > 12.7 mg/L (sensitivity 40%, specificity 93%) and FC > 58.7 μg/g (sensitivity 100%, specificity 47%).

Conclusions

SFCR and biochemical remission prior to upadacitinib de-escalation, but not induction duration, predict lower UCRC risk. Upadacitinib de-escalation should be guided by response assessment rather than a predetermined induction duration.

Schlagwörter

Stichwörter der Autor:innen

Janus Kinase inhibitorsbiomarkersfecal calprotectininflammatory bowel diseaseulcerative colitisupadacitinib

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
  • Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.

ORCID-Profile: Raj M Dalal, Sarah Rotondo-Trivette, Alec R Mason, Lynn Leveille, Jianyi Yin, Chelsea Missi, Moheb Boktor, David I Fudman

Zitieren

APA

Dalal, R. M., Rotondo-Trivette, S., Mason, A. R., Leveille, L., Yin, J., Missi, C., Boktor, M., & Fudman, D. I. (2026). Real-world success of de-escalating upadacitinib induction dosing in ulcerative colitis is predicted by steroid-free clinical and biochemical remission, not induction duration. Crohn’s & Colitis 360, 8(4). https://doi.org/10.1093/crocol/otag111

Vancouver

Dalal RM, Rotondo-Trivette S, Mason AR, Leveille L, Yin J, Missi C, et al. Real-world success of de-escalating upadacitinib induction dosing in ulcerative colitis is predicted by steroid-free clinical and biochemical remission, not induction duration. Crohn’s & Colitis 360. 2026;8(4). doi:10.1093/crocol/otag111

BibTeX
@article{Dalal2026,
  author = {Dalal, Raj M and Rotondo-Trivette, Sarah and Mason, Alec R and Leveille, Lynn and Yin, Jianyi and Missi, Chelsea and Boktor, Moheb and Fudman, David I},
  title = {Real-world success of de-escalating upadacitinib induction dosing in ulcerative colitis is predicted by steroid-free clinical and biochemical remission, not induction duration},
  journal = {Crohn’s & Colitis 360},
  year = {2026},
  volume = {8},
  number = {4},
  doi = {10.1093/crocol/otag111}
}
Kostenlos starten →